Global Therapeutic Landscape for Grass Pollen Allergy: Key Products Under Development - ResearchAndMarkets.com

DUBLIN--()--The "Grass Pollen Allergy - Pipeline Review, H1 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.

This pharmaceutical and healthcare disease pipeline guide provides an overview of the Grass Pollen Allergy (Immunology) pipeline landscape. The pipeline guide provides comprehensive information on the therapeutics under development for Grass Pollen Allergy (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The pipeline guide also reviews of key players involved in therapeutic development for Grass Pollen Allergy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II and Preclinical stages are 2, 4 and 2 respectively.

The pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope of the report:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Grass Pollen Allergy.
  • The pipeline guide reviews pipeline therapeutics for Grass Pollen Allergy (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Grass Pollen Allergy (Immunology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Grass Pollen Allergy (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Grass Pollen Allergy (Immunology)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Grass Pollen Allergy (Immunology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Grass Pollen Allergy (Immunology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Key Topics Covered:

  • Introduction
  • Report Coverage
  • Grass Pollen Allergy - Overview
  • Grass Pollen Allergy - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Products under Development by Companies
  • Grass Pollen Allergy - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Grass Pollen Allergy - Companies Involved in Therapeutics Development
  • ALK-Abello AS
  • Allergy Therapeutics Plc
  • ASIT Biotech SA
  • Biomay AG
  • DC4U BV
  • HAL Allergy BV
  • Regeneron Pharmaceuticals Inc
  • Grass Pollen Allergy - Drug Profiles
  • Allergen for Pollen Grass Allergy Induced Allergic Rhinitis and Rhinoconjunctivitis - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • BM-32 - Drug Profile
  • dupilumab - Drug Profile
  • gp-ASIT - Drug Profile
  • Pollinex Quattro Grass - Drug Profile
  • standardized grass pollen [timothy (Phleum pratense)] allergen extract - Drug Profile
  • Grass Pollen Allergy - Dormant Projects
  • Grass Pollen Allergy - Discontinued Products
  • Grass Pollen Allergy - Product Development Milestones
  • Featured News & Press Releases
  • Appendix
  • Methodology

Companies Mentioned

  • ALK-Abello AS
  • Allergy Therapeutics Plc
  • ASIT Biotech SA
  • Biomay AG
  • DC4U BV
  • HAL Allergy BV
  • Regeneron Pharmaceuticals Inc

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/r62exx

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900